Maravai LifeSciences Holdings, Inc. beat EPS estimates 50% of the time across 16 reported quarters (8 beats, 8 misses), averaging -23.3% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.07 | $-0.07 | +0.0% | Beat | |
| Q1 FY26 | $-0.07 | $-0.03 | +57.1% | Beat | Q1 FY26 call |
| Q4 FY25 | $-0.09 | $-0.07 | +22.2% | Beat | |
| Q3 FY25 | $-0.08 | $-0.14 | -75.0% | Miss | |
| Q2 FY25 | $-0.09 | $-0.12 | -33.3% | Miss | |
| Q1 FY25 | $-0.10 | $-0.15 | -50.0% | Miss | |
| Q4 FY24 | $-0.06 | $-0.14 | -133.3% | Miss | |
| Q3 FY24 | $-0.04 | $-0.09 | -125.0% | Miss | |
| Q2 FY24 | not reported | $-0.08 | not reported | not reported | |
| Q1 FY24 | $-0.06 | $-0.11 | -83.3% | Miss | |
| Q4 FY23 | $-0.04 | $-0.05 | -25.0% | Miss | |
| Q3 FY23 | $-0.03 | $-0.02 | +33.3% | Beat |
Back to MRVI overview · MRVI holders · MRVI KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.